Adhesion receptor antagonists III

US5723480A · kind A · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Joachim Gante · Darmstadt, DE
• Horst Juraszyk · Seeheim-Jugenheim, DE
• Peter Raddatz · Darmstadt, DE
• Hanns Wurziger · Darmstadt, DE
• Guido Melzer · Hofheim, DE
• Sabine Bernotat-Danielowski · Bad Nauheim, DE

Key dates

• Filing date: May 29, 1996
• Grant date: Mar 3, 1998
• Expiry date: May 29, 2016

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel oxazolidinone derivatives of the formula I ##STR1## in which R.sup.1 is a phenyl radical which is unsubstituted or is monosubstituted by CN, H.sub.2 N--CH.sub.2 --, A.sub.2 N--CH.sub.2 --, H.sub.2 N--C(.dbd.NH)--, H.sub.2 N--C(.dbd.NH)--NH--, H.sub.2 N--C(.dbd.NH)--NH--CH.sub.2 --, HO--NH--C(.dbd.NH)-- or HO--NH--C(.dbd.NH)--NH--, PA1 X is O, S, SO, SO.sub.2, --NH-- or --NA--, PA1 B is ##STR2## A is alkyl having from 1 to 6 C atoms, R.sup.2 is H, A, Li, Na, K, NH.sub.4 or benzyl, PA1 R.sup.3 is H or (CH.sub.2).sub.n --COOR.sup.2, PA1 E is, in each case independently of each other, CH or N, PA1 Q is O, S or NH, PA1 m is 1, 2 or 3, and PA1 n is 0, 1, 2 or 3, and physiologically compatible salts thereof are provided, which inhibit the binding of fibrinogen to the corresponding receptor and can be used for treating thrombosis, stroke, cardiac infarction, inflammations, arteriosclerosis, osteoporosis and also tumors.